pirozadil

Known as: 2,6-pyridinediyldimethylene bis(3,4,5-trimethoxybenzoate) 
A nicotinic acid derivative with antilipidemic activity.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1977-1989
02419771989

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1989
1989
With the goal to evaluate the long term efficacy and tolerance of pirozadil, 20 patients with hypercholesterolemia (type II a… (More)
Is this relevant?
1987
1987
Pirozadil (pyridine 2,6-dimethanol-bis(3,4,5-trimethoxybenzoate), Pemix) was administered for 16 weeks at a dose of 1.5 or 2.0 g… (More)
Is this relevant?
1987
1987
The lipid-lowering agent pirozadil was tested in 1185 hyperlipidaemic subjects during a 2-4 months' intake. Plasma triglycerides… (More)
Is this relevant?
1986
1986
Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats. By feeding the animals a high… (More)
Is this relevant?
1982
1982
Pirozadil and alufibrate are compared by a single-blind study over two groups 20 patients with primary hyperlipoproteinemia… (More)
Is this relevant?
1982
1982
 
Is this relevant?
1981
1981
The effect of pirozadil, a new hypolipidemic agent, on cerebral blood flow was tested in anesthetized dogs and compared to that… (More)
Is this relevant?
1978
1978
The hypolipidemic and antiatherogenic effects of different nicotinic acid derivatives were studied. Five rabbit groups maintained… (More)
Is this relevant?